medigraphic.com

2021, Number 3

<< Back Next >>

Rev Fac Med UNAM 2021; 64 (3)

Conceptual Bases of Metabolic Surgery

Arana RJC, Cerón RF, Díaz RJJ, Vázquez PR, Aparicio PR, García FR, Corona BA

Language: Spanish
References: 66
Page: 7-19
PDF size: 476.03 Kb.


ABSTRACT

The term Metabolic Syndrome (MS) has been used since its introduction in 2001 by the National Cholesterol Program (NCEP: ATP III). The concept has been discussed in the scientific literature for decades. The X Syndrome and other terms such as "death quartet" and insulin resistance syndrome have been used to describe the association between metabolic and cardiovascular risk factors. In Mexico, the prevalence of MS in the National Health and Nutrition Survey (Encuesta Nacional de Salud y Nutrición, ENSANUT) was 34% in 2000 and 41% in 2012. Lifestyle modifications along with increased physical activity, quitting smoking, and limiting alcohol consumption are essential for management and prevention because they play a central role in metabolic abnormalities. However, despite the large amount of medications available for diabetes, up to 50% of patients have been reported to fail to achieve adequate control goals, as defined by the American Diabetes Association (glycosylated hemoglobin ‹7%). In contrast, bariatric surgery (BS) has clearly confirmed that it contributes to improved beta cell function in patients with BMI ›35 kg / m2, as well as control of dyslipidemia and other metabolic disorders.


REFERENCES

  1. Expert Panel on Detection, Evaluation, and Treatment of High blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA. 2001;285:2486-97.

  2. Cornier y cols. The Metabolic Syndrome. Endocrine Reviews. 2008;29(7):777-822.

  3. ReavenGM1988 Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.

  4. KaplanNM1989 The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149:1514-20.

  5. DeFronzo RA, Ferrannini E. Insulin resistance. Amultifacetedsyndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-94.

  6. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442-3.

  7. Altan Onat. Metabolic syndrome: nature, therapeutic solutions and optionsExpert Opin. Pharmacother. 2011;12(12): 1887-900.

  8. Asociación Latinoamericana de diabetes. GUIA ALAD SX Met niños. 2010. Disponible en: www.alad-latinoamerica.org http://doi.

  9. Yin y cols. Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front Biosci. 2013;18:638-49.

  10. DeFronzo R. A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270-87.

  11. Hanley AJ, Williams K, Stern MP y cols. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25:1177-84.

  12. Isomaa B, Almgren P, Tuomi T y cols. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.

  13. Pineda Carlos Andrés. Síndrome metabólico: definición, historia, criterios. Colomb Med. 2008;39:96-106.

  14. Alberti KGM, Zimmet PZ. For the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. PART 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetes Med. 1998;15:539-53.

  15. Grundy SM, Cleeman JJ, Daniels SR, y cols. Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17): 2735-52.

  16. Carlos J. Castro-Sansores, Víctor Hernández-Escalante, Ruy Arjona-Villicaña. Prevalencia de Síndrome Metabólico en sujetos adultos que viven en Mérida, Yucatán, México. Rev Biomed. 2011;22:49-58.

  17. Aguilar SCA. High prevalence of the metabolic syndrome in Mexico. Arch Med Res. 2004;35:76-81.

  18. Aguilar SCA. Analysis of the agreement between the WHO criteria and the National Cholesterol Education Program III. Definition of the metabolic syndrome: Results from population based survey. Diabetes Care. 2003;26:1635.

  19. Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE. The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract. 2007;77:471-8.

  20. Harzallah F, Alberti H, Ben Khalifa F. The metabolic syndrome in an Arab population: a first look at the new International. Diabetes Federation criteria. Diabet Med. 2006;23:441-4.

  21. Chien KL, Lee BC, Hsu HC, Lin HJ, Chen MF, Lee YT. Prevalence, agreement and classification of various metabolic syndrome criteria among ethnic Chinese: a report on the hospitalbased health diagnosis of the adult population. Atherosclerosis. 2008;196(2):764-71.

  22. Zabetian A, Hadaegh F, Azizi F Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract. 2007;77:251-7.

  23. Olaiz G, Rojas R, Barquera S, Shamah T, Aguilar-Salinas C, Cravioto P, y cols. Encuesta Nacional de Salud 2000. La salud de los adultos. Cuernavaca, Morelos: Instituto Nacional de Salud Pública, 2003.

  24. ENSANUT 2012. Disponible en: http://www.ensanut. insp.mx

  25. Rojas-Martínez R, Aguilar-Salinas CA, Jiménez-Corona A. Puntos de corte óptimos para la detección de diabetes tipo 2, hipertensión y síndrome metabólico no diagnosticados en adultos mexicanos. Salud Pública Mex. 2012; 54:13-9.

  26. Barquera S, Campos-Nonato I, Hernández-Barrera L, Pedroza- Tobías A, Rivera-Dommarco JA. Prevalence of obesity in Mexican adults, ENSANUT 2012. Salud Publica Mex. 2013;55 suppl 2:S151-S160.

  27. González-Chávez A y cols. Prevalencia del síndrome metabólico. Rev. Med Hosp Gen Mex. 2008;71(1):11-9.

  28. Isordia-Salas I, y cols. Prevalence of Metabolic Syndrome Components in an Urban Mexican Sample: Comparison between Two Classifications. Experimental Diabetes Research. 2012;202540. http://doi/10.1155/2012/202540

  29. Méndez-Hernández P, Flores Y, Siani C. Physical activity and risk of Metabolic Syndrome in an urban Mexican cohort. BMC Public Health. 2009;9:276.

  30. The IDF consensus worldwide definition of the metabolic síndrome. International Diabetes Federation. [acceso 07- sept-2015]. Disponible en: http://www.idf.org/webdata/ docs/IDF_Metasyndrome_definition.pdf.

  31. Martínez-Larrad MT, y cols. Revised waist circumference cut-off points for the criteria of abdominal obesity in the Spanish population: Multicenter nationwide Spanish population based study. Av Diabetol. 2011;27(5):168-74.

  32. Mirrakhimov AE, Lunegova OS, Kerimkulova AS, Moldekeeva CB, Nabiev MP, Mirrakhimov EM. Cut off values for abdominal obesity as a criterion of metabolic syndrome in an ethnic Kyrgyz population (Central Asian region). Cardiovascular Diabetology. 2012;11:16. doi:10.1186/1475-2840-11-16.

  33. Remón-Popa I. Estimación del punto de corte de la circunferencia abdominal como criterio diagnóstico del síndrome Metabólico. Revista Cubana de Medicina Militar. 2013;42(1):29-38.

  34. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270-87.

  35. DeFronzo, Abdul-Ghani. Preservation of Cell Function. J Clin Endocrinol Metab. 2011;96(8):2354-66.

  36. McCarthy MI. Genomics, Type 2 Diabetes, and Obesity. N Engl J Med. 2010;363(24):2339-50.

  37. Miranda-Garduño LM, Reza-Albarrán A. Obesidad, inflamación y diabetes. Gac Méd Méx. 2008;144(1):39-46.

  38. Kim J, Wei Y, Sowers JR. Role of Mitochondrial Dysfunction in Insulin Resistance. Circ. Res. 2008;102:401-14.

  39. Liu Q, Bengmark S, Qu S. The role of hepatic fat accumuhttp lation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis. 2010;9:42.

  40. Flores-Le-Roux JA, Benaiges-Boix D, Botet-Montoya JP. Quemerina: una nueva adipoquina. Clin Invest Arterioscl. 2011;23(4):175-82.

  41. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nature Reviews Immunology. 2011;11(2):85-97.

  42. Ros-Pérez M, Medina-Gómez G. Obesidad, adipogénesis y resistencia a la insulina. Endocrinol Nutr. 2011;58(7):360-9.

  43. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34(31):2436-43.

  44. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. Endothelial Dysfunction in Diabetes The role of reparatory mechanisms. Diabetes Care. 2011;34, Supplement 2:S285-S290.

  45. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, y cols. Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012). Rev Esp Cardiol. 2012;65:e1-66.

  46. Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ. 1997;315:973-80.

  47. Raupach T, Schafer K, Konstantinides S, Andreas S. Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm. Eur Heart J. 2006;27: 386-92.

  48. Steenland K. Risk assessment for heart disease and workplace ETS exposure among nonsmokers. Environ Health Perspect. 1999;107 Suppl 6:859-63.

  49. Inzucchi SE, Bergenstal RM, Buse JB, y col. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.

  50. American Diabetes Association. Standars of medical care in diabetes. Diabetes care 2013 Jan; 36 Suppl 1:11-66.

  51. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, y cols. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818.

  52. Bradley D, Magkos F, Klein S. Effects of Bariatric Surgery on Glucose Homeostasis and Type 2 Diabetes Gastroenterology. 2012 October;143(4):897-912.

  53. Fried M, Yumuk V, Oppert JM, y cols. Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery. Obesity Facts: The European Journal of Obesity. 2013;6:449-68.

  54. Kular KS, Manchanda N, Cheema GK. Seven years of mini-gastric Bypass in type II Diabetes Patients with a body mass index <35Kg/m2. Obes Surg. 2016;26(7):1457- 62. DOI 10.1007/s11695-015-1941-y.

  55. Polymeris A, Karoutsou E, Michalakis K. The Impact of Bariatric Surgery Procedures on Type 2 Diabetes, Hyperlipidemia and Hypertension. Hellenic J Cardiol. 2013; 54:212-7.

  56. Carbajo MA, García-Caballero M, Osorio D, y cols. Oneanastomosis gastric bypass by laparoscopy: Results of the first 209 patients. Obes Surg. 2005;15:398-404.

  57. Carbajo MA, Ortiz de Solórzano J, García-Lanza C, Pérez Miranda M, Fonseca OG, Castro MJ. Bypass gástrico laparoscópico de una sola anastomosis (BAGUA) asistido con brazo robótico: Técnica y resultados en 1,126 pacientes. Cirugía Endoscópica. 2008;9(1):6-13.

  58. Azizi F. Bariatric surgery for obesity and diabetes. Arch Iran Med. 2013;16(3):182-6.

  59. Sjostrom, Narbo K, Sjostrom CD, y cols. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-52.

  60. Dixon JB, O’Brien PE, Playfair J, y cols. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316-23. [PubMed: 18212316].

  61. Schauer PR, Kashyap SR, Wolski K, y cols. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567-76. [PubMed: 22449319].

  62. Mingrone G, Panunzi S, De Gaetano A, y cols. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577-85. [PubMed: 22449317].

  63. Carbajo MA, Vázquez-Pelcastre R, Aparicio-Ponce R, Luque de León E, Jiménez JM, Ortíz-Solorzano J, Castro MJ. 12- year old adolescent with super morbid obesity, treated with laparoscopic one anastomosis gastric bypass (LOAGB/ BAGUA): A case report after 5-year follow-up. Nutrición Hospitalaria. 2015;31(5):2327-32.

  64. Susmallian S, Raziel A, Barnea R, Paran H. Bariatric surgery in older adults, should there be age limit? Medicine. 2019;98:3(e13824).

  65. Parmar C, Abdelhalim MA, Mahawar KK, Boyle M, Carr WRJ, Jennings N, Small PK. Management of super-super obese patients: comparison between one anastomosis (mini) gastric bypass and Roux-en-Y gastric bypass. Surg Endosc. 2017;31(9):3504-9.

  66. Cazzo E, Valerini FG, Chaim FHM, Soares PFC, Ramos AC, Chaim EA. Early weigth loss outcomes and glucose metabolism parameters after banded versus non-banded one anastomosis gastric bypass: a prospective randomized trial. Arq Gastroenterol. 2019;56(1):15-21.




2020     |     www.medigraphic.com